Jubilant Ingrevia to acquire 40% stake in Zettaone for ₹189.2 Cr
Jubilant Ingrevia Limited will acquire a 40% stake in Zettaone Technologies for ₹189.2 crore. The acquisition will be completed in two tranches by November 2026 and September 2027. Zettaone is an electronics design and manufacturing platform.
The acquisition of a 40% stake in Zettaone Technologies for ₹189.2 crore is a significant investment that is expected to enhance the company's capabilities in a new sector, but it is not a full acquisition or a transformative event for the entire company's financial structure.
The acquisition is a strategic move aligned with the company's growth strategy and is expected to create long-term value, indicating a positive outlook.
Jubilant Ingrevia Limited has entered into a binding agreement to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for ₹189.2 crore. This acquisition is in line with Jubilant Ingrevia's Pinnacle growth strategy and aims to strengthen its presence in the Electronics Development and Manufacturing Services (EDMS) sector.
Following the completion of the acquisition, Zettaone will become an associate company of Jubilant Ingrevia. The transaction is expected to be completed in two tranches, with the first tranche closing by November 2026 and the second by September 2027. This move will enable Jubilant Ingrevia to offer an integrated value proposition in the electronics and semiconductor space, leveraging its existing manufacturing and customer-centric capabilities from its CDMO business.
Zettaone Technologies is an integrated electronics design and manufacturing platform offering end-to-end product development solutions. The company serves various industries including aerospace, defence, semiconductor, automotive, medical, and industrial applications. For the last three financial years, Zettaone's turnover was ₹51.1 crore in FY23-24, ₹79.1 crore in FY24-25, and ₹98.1 crore in FY25-26.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.